CLINICAL CASE OF COMPLEX RADICAL TREATMENT OF METASTATIC PROGRESSION TO RARE SITE OF PRIMARY ORGAN CONFINED CHROMOPHOBE RENAL CELL CARCINOMA TREATED WITH LAPAROSCOPIC PARTIAL NEPHRECTOMY
DOI:
https://doi.org/10.15407/exp-oncology.2025.04.506Keywords:
kidney cancer, chromophobe cancer, partial nephrectomy, immunohistochemical study, molecular profile, pembrolizumabAbstract
We present a case of stage I chromophobe renal cell carcinoma, which initially was treated with laparoscopic partial nephrectomy, and four years later progressed to multifocal metastatic nodules in the perirenal adipose capsule without local recurrence in the kidney itself. The curative approach included the surgical complete removal of perirenal adipose tissue with adjuvant pembrolizumab. We discuss the molecular and genetic peculiarities of chromophobe renal cell carcinoma as applied to the diagnosis and a rationale for adjuvant pembrolizumab.
References
Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in onco- logy. J Natl Compr Canc Netw. 2022;20(1):71-90. https://doi.org/10.6004/jnccn.2022.0001
Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma inci- dence and mortality. Eur Urol. 2015;67(3):519-530. https://doi.org/10.1016/j.eururo.2014.10.002
Henske EP, Cheng L, Hakimi AA, et al. Chromophobe renal cell carcinoma. Cancer Cell. 2023;41(8):1383-1388. https://doi.org/10.1016/j.ccell.2023.07.006
Alaghehbandan R, Przybycin CG, Verkarre V, et al. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. Asian J Urol. 2022; 9(1):1-11. https://doi.org/10.1016/j.ajur.2021.11.010
Bigot P, Bernhard JC, Flamand V, et al. Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes. Urol Oncol. 2016;35(1):35.e15-35.e19. https://doi.org/10.1016/j.urolonc.2016.08.012
Singla A, Sharma A, Makkar A, et al. Rare metastatic sites of renal cell carcinoma: a case series. Pan Afr Med J. 2022;42:26. https://doi.org/10.11604/pamj.2022.42.26.33578
Moch H, Ohashi R. Chromophobe renal cell carcinoma: current and controversial issues. Pathology. 2021;53(1):101- 108. https://doi.org/10.1016/j.pathol.2020.09.015
Ökrösi A, Ponhold L, Turba S et al. Liver metastasis from a chromophobe renal cell carcinoma 18 years after initial diagnosis: a case report. J Med Case Reports. 2025;19:116. https://doi.org/10.1186/s13256-025-05154-w
Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008-2016. https://doi.org/10.1016/S0140-6736(16)00559-6
Zhang H, Cong X, Chen C, Liu Z. Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report. Front Oncol. 2024;2(14):1325999. https://doi.org/10.3389/fonc.2024.1325999
Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer: biology and implications for therapy. Cancer Dis- cov. 2013;3(3):203-211. https://doi.org/10.1158/2159-8290.CD-18-1354
Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26(3):319-330. https://doi.org/10.1016/j.ccr.2014.07.014
Ohashi R, Schraml P, Angori S, et al. The molecular features and evolution of the chromophobe renal cell carci- noma. J Pathol. 2019;247(3):303-313. https://doi.org/10.1016/j.ajur.2021.11.010
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carci- noma. N Engl J Med. 2016;374(2):135-145. https://doi.org/10.1056/NEJMoa1505917
El-Shorbagy SH, Alshenawy HA. Diagnostic utility of vimentin, CD117, cytokeratin-7 and caveolin-1 in diffe- rentiation between clear cell renal cell carcinoma, chromophobe renal cell carcinoma and oncocytoma. J Microsc Ultrastruct. 2017;5(2):90-96. https://doi.org/10.1016/j.jmau.2016.07.005
Garje R, Elhag D, Yasin HA, et al. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021;160:103287. https://doi.org/10.1016/j.critrevonc.2021.103287
Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384 (9):829-841. https://doi.org/10.1056/NEJMoa2026982
McDermott DF, Lee JL, Ziobro M, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029-1039. https://doi.org/10.1200/JCO.20.02365
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
